SUNPHARMA vs TCS: Stock Comparison
TATA CONSULTANCY SERV LT is the larger company by market capitalisation. SUN PHARMACEUTICAL IND L shows faster revenue growth, while TATA CONSULTANCY SERV LT shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
SUNPHARMA leads 5; TCS leads 8 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | SUNPHARMA | TCS |
|---|---|---|
| Sector | Healthcare | Information Technology |
| Industry | Pharmaceuticals | Computers - Software & Consulting |
Price
| Metric | SUNPHARMA | TCS |
|---|---|---|
| Live Price | ₹1,760 | ₹2,156 |
| Day Change | 0.01% | 3.85% |
| Volume | 13.46 L | 1.17 Cr |
| 52-Week High | ₹2,046.9 | ₹3,350 |
| 52-Week Low | ₹1,583.7 | ₹1,976.8 |
| Distance from 52W High | -14.02% | -35.64% |
Valuation
| Metric | SUNPHARMA | TCS |
|---|---|---|
| Market Cap | ₹4.22 L Cr | ₹7.83 L Cr |
| P/E Ratio | 34.85x | 15.16x |
| P/B Ratio | 5.04x | 6.58x |
| EPS | ₹12.06 | ₹36.9 |
| Book Value | ₹349.6 | ₹299.82 |
| Dividend Yield | 0.91% | 3.01% |
Growth
| Metric | SUNPHARMA | TCS |
|---|---|---|
| Revenue Growth (TTM YoY) | 12.8% | 9.6% |
| EPS Growth (TTM YoY) | 25.6% | 12.2% |
| Qtr Sales Growth | 4.71% | 2.23% |
| Qtr Profit Growth | 7.07% | -2.64% |
Profitability & Leverage
| Metric | SUNPHARMA | TCS |
|---|---|---|
| ROE | 11.76% | 57.98% |
| ROCE | 9.6% | 60.71% |
| Net Margin | 18.56% | 18.58% |
| Operating Margin | 22.81% | 28.94% |
| Debt to Equity | 0.6x | 0x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | SUNPHARMA | TCS |
|---|---|---|
| Promoter Holding | 54.48% | 71.77% |
| FII Holding | 14.53%▼ 1.4 pp | 9.06%▼ 0.6 pp |
| DII Holding | 22.18%▲ 1.07 pp | 13.47%▲ 0.06 pp |
| Public Holding | 8.81%▲ 0.33 pp | 5.69%▲ 0.53 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: SUN PHARMACEUTICAL IND L and TATA CONSULTANCY SERV LT.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.